Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Dose Titration Study of Botulinum Toxin Type A to Treat Spasticity in the Leg and Arm

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Upper and lower limb spasticity of the same body side due to cerebral causes~* Time since event leading to spasticity in the target body side greater than 12 weeks~* Need for 800 units Botulinum toxin type A~Exclusion Criteria:~* Body weight below 50kg~* Fixed contractures of the target joint~* Generalized disorders of muscle activity like Myasthenia gravis that preclude use of Botulinum toxin type A~* Infection at the injection site

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- IncobotulinumtoxinA (Xeomin) (up to 800 Units) (Type: EXPERIMENTAL): IncobotulinumtoxinA (Xeomin, also known as NT 201 or Botulinum toxin type A (150 kiloDalton), free from complexing proteins) (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection

Based on this trial design, predict the completion outcome and termination type (if applicable).